Literature DB >> 9360253

Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study.

P I Bergkvist1, K Sjöbeck.   

Abstract

112 patients admitted to hospital with a diagnosis of erysipelas, were randomized to 8 days treatment with prednisolone or placebo in addition to antibiotics. 108 patients received the study drugs and were evaluated for time to cure, which was the primary end-point. The median healing time was significantly shorter in the prednisolone group, 5 days, vs 6 days in the placebo group (p < 0.01). The 90th percentile healing time was 10.0 days in the prednisolone group vs 14.6 days in the control group. The prednisolone-treated patients had a median length of hospital stay (secondary end-point) of 5 days vs 6 for the placebo-treated (p < 0.01). The median treatment time with intravenous antibiotics (secondary end-point) was 4 days in the placebo group, which was 1 day longer than in the prednisolone group (p < 0.05). 13 patients, 7 of whom received placebo, relapsed during the observation period of 3 weeks. The frequency of side effects attributable to the study drug was not higher in the prednisolone group.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360253     DOI: 10.3109/00365549709011834

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

1.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

2.  Meta-analysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas.

Authors:  Athena Ferreira; Mark J Bolland; Mark G Thomas
Journal:  Infection       Date:  2016-04-16       Impact factor: 3.553

3.  Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial.

Authors:  Philippe Bernard; Olivier Chosidow; Loïc Vaillant
Journal:  BMJ       Date:  2002-10-19

Review 4.  The impact of antibiotics on clinical response over time in uncomplicated cellulitis: a systematic review and meta-analysis.

Authors:  Krishan Yadav; Natalia Krzyzaniak; Charlotte Alexander; Anna Mae Scott; Justin Clark; Paul Glasziou; Gerben Keijzers
Journal:  Infection       Date:  2022-05-20       Impact factor: 7.455

5.  Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure.

Authors:  Claudia Ihm; Jesse D Sutton; Tristan T Timbrook; Emily S Spivak
Journal:  Open Forum Infect Dis       Date:  2019-05-07       Impact factor: 3.835

Review 6.  Interventions for cellulitis and erysipelas.

Authors:  Sally A Kilburn; Peter Featherstone; Bernie Higgins; Richard Brindle
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

7.  Bacterial Etiology and Risk Factors Associated with Cellulitis and Purulent Skin Abscesses in Military Trainees.

Authors:  Ryan C Johnson; Michael W Ellis; Carey D Schlett; Eugene V Millar; Patrick T LaBreck; Deepika Mor; Emad M Elassal; Jeffrey B Lanier; Cassie L Redden; Tianyuan Cui; Nimfa Teneza-Mora; Danett K Bishop; Eric R Hall; Kimberly A Bishop-Lilly; D Scott Merrell
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

8.  Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors.

Authors:  Trond Bruun; Oddvar Oppegaard; Karl Ove Hufthammer; Nina Langeland; Steinar Skrede
Journal:  Clin Infect Dis       Date:  2016-07-11       Impact factor: 9.079

9.  Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice.

Authors:  Manli Na; Wanzhong Wang; Ying Fei; Elisabet Josefsson; Abukar Ali; Tao Jin
Journal:  PLoS One       Date:  2017-03-06       Impact factor: 3.240

10.  Comparative evaluation of 2 g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections.

Authors:  Sudipta Kumar Dey; Amal Kanti Das; Sumit Sen; Avijit Hazra
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.